Shares of Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) ended Thursday session in red amid volatile trading. The shares closed down -0.05 points or -0.10% at $51.90 with 3.57 million shares getting traded. Post opening the session at $52.02, the shares hit an intraday low of $51.40 and an intraday high of $52.28 and the price vacillated in this range throughout the day. The company has a market cap of $52.72 billion and the numbers of outstanding shares have been calculated to be 1.01 billion shares.
Teva Pharmaceutical Industries Ltd (ADR) (TEVA) on September 15, 2016 announced the launch of an authorized generic of Cubicin®1 (daptomycin for injection) 500 mg per vial in the United States.
Daptomycin for injection is an antibacterial drug indicated in adults for the treatment of complicated skin and skin structure infections (cSSSI) caused by susceptible isolates of the following Gram-positive bacteria: Staphylococcus aureus (including methicillin-resistant isolates), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus dysgalactiae subspecies equisimilis, and Enterococcus faecalis (vancomycin-susceptible isolates only).
Daptomycin for injection is indicated in adults for the treatment of Staphylococcus aureus bloodstream infections (bacteremia), including those with right-sided infective endocarditis, caused by methicillin-susceptible and methicillin-resistant isolates.
Daptomycin for injection is not indicated for the treatment of pneumonia. Daptomycin for injection is not indicated for the treatment of left-sided infective endocarditis (LIE) due to S. aureus. Daptomycin for injection has not been studied in patients with prosthetic valve endocarditis.
Shares of Celgene Corporation (NASDAQ:CELG) ended Thursday session in green amid volatile trading. The shares closed up +1.29 points or 1.22% at $107.35 with 3.49 million shares getting traded. Post opening the session at $106.13, the shares hit an intraday low of $105.44 and an intraday high of $107.71 and the price vacillated in this range throughout the day. The company has a market cap of $81.40 billion and the numbers of outstanding shares have been calculated to be 775.11 million shares.
On September 13, 2016 Celgene Corporation (CELG) and the National Psoriasis Foundation (NPF) have united to mark Wednesday, September 28th as the first-ever Psoriatic Arthritis (PsA) Awareness Day—a day dedicated to raising public awareness around the importance of recognition, diagnosis, and treatment. People are encouraged to join the movement at GoPsADay.com to learn factors associated with PsA, help spread the word via their social channels, and to stand up and be counted for those living with this disease.
More than 1 million Americans live with PsA, although this number may be higher given it is often underreported and misdiagnosed—particularly as symptoms are sometimes confused with other types of arthritis such as rheumatoid arthritis, gout, and reactive arthritis. Some factors associated with PsA include pitted fingernails, swollen fingers and toes, foot pain, joint stiffness and/or pain, and a personal or family history of psoriasis or arthritis.
Early recognition, diagnosis, and treatment of psoriatic arthritis is critical for anyone living with the disease. Those who are experiencing any of the common symptoms of PsA should contact their healthcare provider.
“Psoriatic arthritis can present significant challenges to those living with the disease, including significant pain and swelling in joints that may impact a person’s activities of daily living,” said Madelaine Feldman, MD, rheumatologist. “While there is no cure, PsA can be managed, which is why it is critical for people to know the factors associated with PsA, talk with their healthcare provider to obtain the right diagnosis, and determine a treatment plan that works for them.”